Semaglutide vs Tirzepatide vs Retatrutide: Head-to-Head Comparison

Mechanism of Action: What Each Compound Actually Does

Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone that tells your pancreas to release insulin and your brain you're full. The result: reduced appetite, lower blood sugar, slower gastric emptying.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. It hits both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP plays a role in energy storage and appetite regulation. Hitting both may produce synergistic effects on body weight reduction. Jastreboff et al., 2023.

Retatrutide (formerly LY3437943) is a triple agonist — it targets GLP-1, GIP, and glucagon receptors. The glucagon receptor activation increases energy expenditure via thermogenesis and lipolysis. Early phase 2 data shows the strongest weight loss signal of the three. Jastreboff et al., 2023 (SURPASS-2 equivalent).

Half-Life Comparison

Half-life determines dosing frequency and steady-state stability. Here's how they compare:

Semaglutide's longer half-life means more stable receptor engagement, which may translate to fewer hunger spikes between doses. Use the GLP-1 Calculator to model your dosing schedule and see when you'll hit steady state.

Weight Loss: The Clinical Data

This is where the compounds diverge most significantly.

Retatrutide's phase 2 data showed 24% mean weight reduction at 48 weeks — an unprecedented figure for a non-surgical intervention. However, it is still in phase 3 trials and not FDA-approved as of April 2026.

Tirzepatide's dual mechanism appears to outperform semaglutide's GLP-1 mono-action on weight reduction. Both are FDA-approved and available.

Side Effect Profiles

All three compounds share a similar side effect class: GI-related. Nausea, vomiting, diarrhea, constipation. The mechanism — GLP-1-induced slowed gastric emptying — explains this.

FDA's adverse event database shows reports for all GLP-1 agonists related to gallbladder disease and, rarely, pancreatitis. These are not unique to one compound but appear dose and duration dependent.

Which One Is Right for You?

There's no universally correct answer. Here's a practical breakdown:

• Choose Semaglutide if you want the most established safety profile (FDA-approved 2017 for diabetes, 2021 for obesity), are new to GLP-1 therapy, or have insurance coverage that favors older compounds.
• Choose Tirzepatide if you want higher weight loss efficacy without an investigational compound. The GIP co-activation appears to enhance both the magnitude and tolerability of weight reduction. FDA-approved 2022.
• Watch Retatrutide if you're following the pipeline closely. Phase 3 results are expected 2026–2027. If the weight loss signal holds and safety is clean, it may become the preferred option in the next 2–3 years.